Flunitrazolam Pellets – 0.25mg
€ 15,00 – € 52,00Price range: € 15,00 through € 52,00
Flunitrazolam Pellets 0.25mg are described as compressed research materials with a nominal flunitrazolam content of 0.25 mg per pellet.
Flunitrazolam belongs to the triazolobenzodiazepine class and is associated with GABA-A receptor pharmacology.
The source identifies analytical research contexts involving compound identification, chromatographic characterization, spectroscopic analysis, and forensic toxicology.
The stated chemical formula and molecular weight are inconsistent and require verification before being presented as confirmed specifications.
The nominal pellet content does not establish measured active ingredient content or content uniformity.
The source reports ingredient purity of at least 98%, third-party testing, batch traceability, and independent verification of pellet uniformity.
No batch-specific Certificate of Analysis, validated content-uniformity report, or independent analytical documentation was supplied to substantiate these claims.
The source recommends freezer storage at approximately −20°C, protected from light and moisture. No product-specific stability study was supplied.
Flunitrazolam is a potent psychoactive benzodiazepine-related substance associated with risks including profound sedation, impaired consciousness, respiratory depression, and dependence.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
Flunitrazolam Pellets 0.25mg – Research Material Information
Flunitrazolam Pellets 0.25mg – Product Overview
The supplied material is described as compressed research pellets containing a nominal 0.25 mg of flunitrazolam per unit.
Flunitrazolam belongs to the triazolobenzodiazepine class of psychoactive compounds.
The source identifies laboratory contexts involving analytical characterization, chromatographic analysis, spectroscopic identification, and forensic toxicology.
It reports high ingredient purity, independent testing, and pellet content uniformity.
No batch-specific analytical documentation was supplied to substantiate these claims.
The nominal content is a supplier specification, not an independently verified assay result.
The material has not been demonstrated to be a certified reference material or validated quantitative calibrator.
Chemical Identity & Classification
Flunitrazolam is a triazolobenzodiazepine associated with GABA-A receptor pharmacology.
The supplied specifications are:
- Compound: Flunitrazolam
- Chemical class: Triazolobenzodiazepine
- Product form: Compressed laboratory pellets
- Nominal content: 0.25 mg per pellet
- Supplied chemical name: 8-bromo-6-(2-fluorophenyl)-1-methyl-4H-triazolo[4,3-a]benzodiazepine
- Supplied molecular formula: C17H12BrFN6O
- Supplied molecular weight: 371.20 g/mol
- CAS number: Not assigned, according to the source
The supplied formula and molecular weight are inconsistent.
C17H12BrFN6O corresponds to an approximate molecular weight of 415.23 g/mol, rather than 371.20 g/mol.
The supplied chemical name also requires independent verification against the identity of flunitrazolam.
A commonly reported molecular formula for flunitrazolam is C17H12FN5, with a molecular weight of approximately 305.31 g/mol.
These discrepancies prevent confirmation of the product’s stated chemical identity from the supplied information alone.
Public chemical-reference information can be reviewed through PubChem.
Chemical & Physical Characteristics
The source describes compressed laboratory pellets intended for analytical handling.
No independently verified pellet dimensions, average unit weight, excipient composition, hardness, friability, or dissolution characteristics were supplied.
The stated 0.25 mg refers to nominal flunitrazolam content, not total pellet mass.
No measured solubility values, thermal-characterization data, or validated physical-property report was provided.
Pellet appearance and physical uniformity alone do not establish chemical identity or active ingredient content.
Purity & Analytical Verification
The source reports typical ingredient purity of at least 98%.
It also claims third-party verification of chemical identity, purity, and pellet uniformity.
No chromatograms, mass spectra, NMR spectra, impurity profiles, or batch-specific Certificate of Analysis were supplied.
The reported purity therefore remains unverified.
The brief identifies HPLC, LC-MS, and NMR spectroscopy as relevant analytical techniques.
These methods can provide complementary information concerning chemical composition and structure.
Ingredient purity, active ingredient content per pellet, and unit-to-unit content uniformity are separate analytical properties.
A high ingredient-purity result would not, by itself, verify that each pellet contains 0.25 mg.
No validated method-performance data or certified quantitative reference values were provided.
Quality Control & Batch Integrity
The source claims batch-specific tracking, independent testing, content-uniformity verification, and manufacturing under ISO-compliant conditions.
No manufacturing certification, accreditation record, batch-traceability report, or independent analytical documentation was supplied.
The phrase “ISO-compliant” does not identify a particular standard or establish certification.
The stated availability of a third-party Certificate of Analysis upon request does not establish that a particular batch has been independently verified.
The claims concerning pellet uniformity require analytical evidence specific to the finished product.
These quality-control statements remain unverified supplier claims.
Safety, Handling & Laboratory Precautions
Flunitrazolam is a potent psychoactive benzodiazepine-related compound.
Benzodiazepine-related hazards include sedation, impaired judgment, memory disturbance, reduced coordination, dependence, and potentially severe withdrawal.
Respiratory depression and loss of consciousness are particularly concerning in exposures involving other central nervous system depressants.
The toxicological profile of flunitrazolam remains incompletely characterized.
Institutional chemical-safety procedures should address restricted access, protective equipment, contamination prevention, accidental-exposure response, secure custody, and appropriate waste management.
No verified product-specific Safety Data Sheet was supplied.
No human or veterinary application is established or endorsed.
Packaging, Labeling & Storage
The source describes child-resistant containers with chemical research labeling.
It recommends freezer storage at approximately −20°C, protected from light and moisture.
No validated product-specific stability study was supplied to establish this temperature as necessary or sufficient.
No verified shelf life, packaging-barrier performance, or long-term stability dataset was provided.
Child-resistant packaging was claimed but not independently documented.
Laboratory labels should distinguish nominal content and supplier-reported specifications from independently verified batch measurements.
Intended Research Use & Market Positioning
The source identifies analytical laboratory contexts involving benzodiazepine analogue identification, chromatographic profiling, spectroscopic characterization, and forensic chemical analysis.
It also refers to GABA-A receptor research.
No certified reference-material status, validated quantitative calibration performance, or independently verified receptor-binding dataset was supplied.
The provided Raw Lab Chems catalog references are:
These references concern related but chemically distinct benzodiazepine-related compounds.
They should not be represented as interchangeable substances or analytically equivalent materials.
Ordering, Availability & Fulfillment
The source claims worldwide shipping, tracking, protective packaging, and regulatory compliance.
No current inventory record, carrier authorization, transport classification, or supporting shipping documentation was supplied.
These claims cannot be independently confirmed.
Research-only labeling does not automatically exempt a psychoactive substance from controlled-substance legislation, analogue laws, or import restrictions.
Transport eligibility and legal authorization depend on the applicable jurisdiction and transaction.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
Flunitrazolam is a psychoactive benzodiazepine-related substance that may be subject to controlled-substance, analogue, chemical-safety, import, or export restrictions.
Institutions are responsible for verifying applicable legal requirements and maintaining appropriate authorization, laboratory controls, and secure custody.
No therapeutic approval, consumer-use authorization, or certified reference-material status is implied.
| Quantity (pellets) |
5 ,10 ,25 ,50 ,100 |
|---|
You must be logged in to post a review.

Reviews
There are no reviews yet.